Market Overview

Finch Therapeutics Expands Its Leading Microbiome IP Estate with Six New Patents

Share:

Finch Therapeutics Group, Inc. (Finch),
a clinical-stage microbiome therapeutics company, announced today that
the U.S. Patent and Trademark Office (USPTO) has issued six new patents
to Finch covering its Full-Spectrum Microbiota (FSM) and Rationally-Selected
Microbiota (RSM)
product platforms. The additional IP includes:

  • U.S. Patent No. 10,022,406 broadly covers donor-derived compositions.
    It is solely owned by Finch and provides coverage until at least 2031.
  • U.S. Patent No. 9,962,413 broadly covers the use of screened, healthy
    donors in the manufacture of microbial therapies. It is solely owned
    by Finch and provides coverage until at least 2031.
  • U.S. Patent No. 9,901,603 broadly covers lyophilized formulations of
    microbial therapies. It is solely owned by Finch and provides coverage
    until at least 2036.
  • U.S. Patent Nos. 9,968,638 and 10,028,980 broadly cover microbial
    therapies delivered via oral capsules. These patents are exclusively
    licensed from the Regents of the University of Minnesota and provide
    coverage through at least 2032.
  • U.S. Patent No. 9,962,414 broadly covers pharmaceutical compositions
    containing a plurality of Clostridium species. It is solely
    owned by Finch and provides coverage until at least 2021.

This IP is based on the pioneering research of Finch's scientific
advisor and co-founder, Dr. Tom Borody, and its academic collaborators
at the University of Minnesota, Dr. Alex Khoruts and Dr. Michael
Sadowsky.

"After more than 30 years of translational research developing microbial
therapies for patients, I'm thrilled to see the latest additions to
Finch's patent estate which leave the Company uniquely positioned to
continue to unlock the therapeutic potential of the microbiome," said
Tom Borody, M.D. who is a named inventor on 27 of Finch's patents.

Finch's industry-leading patent portfolio consists of 34
issued
U.S. and foreign patents and more than 60 pending patent
applications, which have broad applicability across the microbiome
field. Reflecting the early leadership of its founders in building this
field, Finch's patent portfolio includes composition of matter patents
with priority dates as early as 2000, the earliest in the industry. This
broad estate covers both FSM and RSM products, with issued
claims covering pharmaceutical compositions containing bacterial strains
of the genus Clostridium among other important composition of
matter and method of use claims.

About Finch Therapeutics Group, Inc.

Finch
Therapeutics Group, Inc. (Finch)
is developing novel microbial
therapies to serve patients with serious unmet medical needs. Built on
30 years of translational research at OpenBiome, MIT, University of
Minnesota and the Center for Digestive Diseases, Finch uses Human-First
Discovery
to develop therapies from microbes that have demonstrated
clinically significant impacts on patient outcomes. Finch is unique in
having both a donor-derived Full-Spectrum Microbiota (FSM)
product platform and a Rationally-Selected Microbiota (RSM)
product platform based on microbes grown in pure culture. Finch has an
extensive IP portfolio consisting of 34 issued patents with the earliest
priority dates in the industry and deep operational experience,
including the largest stool donation program in the world, from which
Finch manufactures approximately 1,000 microbial treatments every month.
Finch's lead program, CP101, is an investigational FSM product
for recurrent C. difficile infections. Finch's RSM
platform employs machine-learning algorithms to mine Finch's unique
clinical datasets, reverse engineering successful clinical experience
with FSM to identify the key microbes driving patient outcomes.
Finch has a strategic partnership with Takeda to develop FIN-524, an
investigational RSM product for inflammatory bowel disease. Finch
is using a rich foundation of clinical data to advance its growing
pipeline of FSM and RSM products, leveraging
proof-of-principle results to evaluate target indications and inform the
design of this new therapeutic class.

Full-Spectrum Microbiota, FSM, Rationally-Selected
Microbiota
, RSM, and Human-First Discovery are
trademarks of Finch Therapeutics Group, Inc.

View Comments and Join the Discussion!